Wedbush Analysts Increase Earnings Estimates for APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Wedbush lifted their FY2029 EPS estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, March 3rd. Wedbush analyst L. Chico now forecasts that the company will earn $3.79 per share for the year, up from their prior estimate of $3.77. Wedbush has a “Neutral” rating and a $29.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.73) EPS.

Several other equities research analysts have also commented on the stock. Wells Fargo & Company dropped their price target on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada cut their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a report on Monday. Oppenheimer decreased their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Needham & Company LLC dropped their price target on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price objective on the stock. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.71.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $24.06 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals has a 12 month low of $23.81 and a 12 month high of $66.00. The company has a fifty day moving average price of $29.88 and a two-hundred day moving average price of $31.48. The company has a market cap of $2.99 billion, a PE ratio of -11.85 and a beta of 0.96.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC increased its holdings in Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after acquiring an additional 758 shares during the last quarter. Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. Signaturefd LLC raised its stake in shares of Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in Apellis Pharmaceuticals in the third quarter valued at about $56,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,816 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $33.81, for a total value of $95,208.96. Following the sale, the insider now owns 55,560 shares of the company’s stock, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $62,279.00. Following the transaction, the chief financial officer now owns 88,100 shares of the company’s stock, valued at approximately $2,528,470. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 60,365 shares of company stock worth $1,810,479. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).